Abivax: 600th patient enrolled in UC trial
(CercleFinance.com) - Abivax announces that the 600th patient has been enrolled in the phase 3 ABTECT trial at the end of July 2024.
The ABTECT phase 3 trial is evaluating Obefazimod in moderately to severely active ulcerative colitis (UC).
The Company confirms its forecast to reach full enrolment early in Q1 2025.
Obefazimod, Abivax's lead drug candidate, is an orally administered small molecule that has been shown to enhance the expression of a single microRNA, miR-124.
Phase 2 clinical trials in UC patients generated positive initial data, leading to the launch of a pivotal global Phase 3 clinical program (ABTECT program), with the first patients enrolled in the US in October 2022.
The launch of a phase 2b clinical trial in Crohn's disease is scheduled for the third quarter of 2024, and the evaluation of a possible combination therapy for the treatment of UC is underway, the company says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The ABTECT phase 3 trial is evaluating Obefazimod in moderately to severely active ulcerative colitis (UC).
The Company confirms its forecast to reach full enrolment early in Q1 2025.
Obefazimod, Abivax's lead drug candidate, is an orally administered small molecule that has been shown to enhance the expression of a single microRNA, miR-124.
Phase 2 clinical trials in UC patients generated positive initial data, leading to the launch of a pivotal global Phase 3 clinical program (ABTECT program), with the first patients enrolled in the US in October 2022.
The launch of a phase 2b clinical trial in Crohn's disease is scheduled for the third quarter of 2024, and the evaluation of a possible combination therapy for the treatment of UC is underway, the company says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.